Minireviews
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2020; 26(43): 6770-6781
Published online Nov 21, 2020. doi: 10.3748/wjg.v26.i43.6770
Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
Cristina Maria Muzica, Carol Stanciu, Laura Huiban, Ana-Maria Singeap, Catalin Sfarti, Sebastian Zenovia, Camelia Cojocariu, Anca Trifan
Cristina Maria Muzica, Carol Stanciu, Laura Huiban, Ana-Maria Singeap, Catalin Sfarti, Sebastian Zenovia, Camelia Cojocariu, Anca Trifan, Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, St. Spiridon Emergency Hospital, Iasi 700115, Romania
Author contributions: Trifan A, Stanciu C and Muzica CM contributed to conception and design of the study; Singeap AM, Cojocariu C and Huiban L were involved in the acquisition of data and contributed to the analysis and interpretation of data; Muzica CM, Zenovia S and Stanciu C drafted the manuscript; Sfarti C reviewed the paper; all authors have read and approved the final version of the manuscript; and all authors accept responsibility for its content.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Anca Trifan, FRCP (C), MD, PhD, Doctor, Professor, Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, St. Spiridon Emergency Hospital, University Street 16, Iasi 700115, Romania. ancatrifan@yahoo.com
Received: July 16, 2020
Peer-review started: July 16, 2020
First decision: September 14, 2020
Revised: September 27, 2020
Accepted: October 20, 2020
Article in press: October 20, 2020
Published online: November 21, 2020
Processing time: 126 Days and 13.5 Hours
Core Tip

Core Tip: The risk of hepatocellular carcinoma (HCC) occurrence or recurrence in patients with chronic hepatitis C virus (HCV) infection receiving direct acting antivirals (DAAs) has been debated through the last 4 years. Data provided by current literature indicate a decreasing incidence rate of HCC (both de novo and recurrent) in patients with chronic hepatitis C, HCV-related cirrhosis, and HCV-related HCC after achieving sustained virological response with DAAs.